Medizinische Hochschule Hannover

Helmholtz-zentrum Fur Infektionsforschung Gmbh

Twincore, Zentrum Fur Experimentelle Und Klinische Infektionsforschung Gmbh

Helmholtz-zentrum Für

Infektionsforschung Gmbh

Hans-Peter Prochnow

Mark Brönstrup

Rolf Müller

Jennifer Herrmann

Thomas Pietschmann

Thomas Schulz

Martin Messerle

Sibylle Haid

Sebastian Blockus

Christine Laqmani-Goffinet

Sergej Franz

Dominic Howard Banda

Giambattista Testolin

Charlotte Grandclaudon

Nv Suryanarayana Birudukota

Tim Mollner

Antje Ritter

The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g. for treating an infectious disease caused by an infection with RSV, KSHV, CMV, DENV, CHIKV, TBEV, VSV, ZIKV and/or HCV.

Labyrinthopeptins as anti-viral agents

The present invention relates to novel derivatives of cystobactamides of formula (Ib) and the use thereof for the treatment or prophylaxis of bacterial infections. 

Cystobactamide derivatives

Growing community of inventors

Braunschweig, Germany

Hans-Peter Prochnow